Table 1.
Cancer types | Cell lines used | Biomarker identified | Clinical relevance | Quantitative techniques used | Reference |
---|---|---|---|---|---|
Breast cancer | 21T series of Breast cancer cell lines HMT-3522-S1, MFM223, HCC202 and HCC2218, HCC1599, HCC1143, HCC1937, MCF7, MCF10A, MDA-MB-453 |
TIMM 17A IDH2, CRABP2, SEC14L2 |
Disease prognosis Disease progression and monitoring |
SILAC and LC-MS/MS SILAC and MALDI-MS/MS |
[5] [44] |
| |||||
Prostate cancer | PC3, LnCAP, 22Rv1 | Follistatin, chemokine (C-X-C motif) ligand 16, Pentraxin 3, and spondin 2 | Disease progression and monitoring | Two-dimensional chromatography and tandem mass spectrometry 2D-DIGE, MALDI-MS/MS |
[76] [92] |
| |||||
Lung cancer | 1198 and 1170-I, BEAS-2B and 1799 CL1-0 and CL1-5 |
PGP9.5, TCTP, TIMP-2, and TPI KPNA2 |
Disease monitoring Disease detection and progression monitoring |
2DE and MS SILAC, LC-MS/MS |
[81] [46] |
| |||||
Gastric cancer |
AGS and MKN7 |
GRN |
Disease detection and monitoring | 2D-LC-MS/MS and iTRAQ | [93] |
| |||||
Pancreatic cancer | PANC1, BxPc3, MIA-PaCa2, SU.86.86 | Anterior gradient homolog 2, syncollin, olfactomedin-4, polymeric immunoglobulin receptor, and collagen alpha-1(VI) chain |
Early disease detection and monitoring | LC-MS/MS, ELISA | [94] |
| |||||
Colorectal cancer | Tumor samples were cultured in vitro | EFEMP2 | Detection and monitoring | 1D-LC-MS/MS | [95] |
| |||||
Head and Neck cancer | SCC4, HSC2, SCC38, and AMOSIII | alpha-enolase, peptidyl prolyl isomerase A/cyclophilin A, 14-3-3 z, heterogeneous ribonucleoprotein K, and 14-3-3 s | Disease detection and progression monitoring | LC-MS/MS, western blot | [96] |
| |||||
Oral cancer | OEC-M1 and SCC4 OEC-M1 and SCC4 |
Mac-2 BP Guanylate-binding protein 1 (GBP1) |
Early detection of disease Disease detection and progression |
MALDI-TOF MS 1D and LC-MS/MS |
[97] [98] |
| |||||
Renal cell carcinoma | 786-O, Caki-1, A498, ACHN OS-RC-2, HK-2, HUVEC | FoxM1 | Detection and potential drug target | IHC, western blot, ELISA | [99] |